<!DOCTYPE html>
<!-- saved from url=(0095)https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm -->
<html class="" data-reactroot=""><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><script src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/analytics.js.download" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app218.us.archive.org';v.server_ms=479;archive_analytics.send_pageview({});});</script>
<script type="text/javascript" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/bundle-playback.js.download" charset="utf-8"></script>
<script type="text/javascript" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/wombat.js.download" charset="utf-8"></script>
<script type="text/javascript">
  __wm.init("https://web.archive.org/web");
  __wm.wombat("https://baike.sogou.com/kexue/d15537804402491912.htm","20221028215537","https://web.archive.org/","web","/_static/",
	      "1666994137");
</script>
<link rel="stylesheet" type="text/css" href="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/banner-styles.css">
<link rel="stylesheet" type="text/css" href="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/iconochive.css">
<!-- End Wayback Rewrite JS Include -->
<meta name="save" content="history"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="baidu-site-verification" content="VWGb6TyYx8"><meta content="表皮生长因子受体 - 搜狗科学百科" name="keywords"><meta content="搜狗科学百科是一部有着平等、协作、分享、自由理念的网络科学全书，为每一个互联网用户创造一个涵盖所有领域知识、服务的中文知识性平台。" name="description"><meta http-equiv="x-dns-prefetch-control" content="on"><meta name="server" baike="235" ip="210" env="online"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://cache.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://hhy.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://pic.baike.soso.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://ugc.qpic.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://xui.ptlogin2.qq.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://q1.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://q2.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://q3.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://q4.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://q.qlogo.cn/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://img01.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://img02.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://img03.sogoucdn.com/"><link rel="dns-prefetch" href="https://web.archive.org/web/20221028215537/https://img04.sogoucdn.com/"><link rel="Shortcut Icon" href="https://web.archive.org/web/20221028215537im_/https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link rel="Bookmark" href="https://www.sogou.com/images/logo/new/favicon.ico?v=4"><link href="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/base_b849887.css" rel="stylesheet"><link href="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/detail_378aed5.css" rel="stylesheet"><link href="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/inviteAudit_7894507.css" rel="stylesheet"><link rel="stylesheet" href="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/highlight.min.css"><title>表皮生长因子受体 - 搜狗科学百科</title><style>.onekey-close {
	position: absolute;
	top: 16px;
	right: 16px;
	width: 24px;
	height: 24px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	text-indent: -999em;
	background-size: 84px;
	background-position: -63px 0;
}

.onekey-login {
	position: absolute;
	top: 16.4%;
	left: 0;
	right: 0;
	width: 100%;
}

/* .onekey-login-img {
    width: 75px;
    height: 75px;
    background: url("https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/images/sprite_wap_baike.png") no-repeat;
    background-size: 100px 91px;
    background-position: 0 0;
    background-repeat: no-repeat;
    margin: 0 auto;
} */

.onekey-login-title {
	text-align: center;
	padding-bottom: 3px;
	font-size: 21px;
	font-weight: bold;
	line-height: 30px;
	color: #000;
}

.onekey-login-txt {
	text-align: center;
	font-family: PingFangSC;
	font-size: 14px;
	line-height: 20px;
	color: #8f8f8f;
}

.onekey-login-qq,
.onekey-login-wx,
.onekey-login-phone {
	display: block;
	width: 245px;
	height: 54px;
	border-radius: 45px;
	text-align: center;

	margin: 0 auto;
	font-size: 17px;
	line-height: 24px;
	color: #000;
	/* padding: 16px 77px; */
	border-radius: 12px;
	border: solid 1px #e0e0e0;
}
.onekey-qq-content,
.onekey-vx-content,
.onekey-phone-content {
	display: inline-block;
	margin-top: 16px;
}
.onekey-qq-content {
	padding: 0 5px;
}

.onekey-login-qq {
	margin-top: 48px;
	margin-bottom: 24px;
}

.onekey-login-qq:before {
	display: inline-block;
	content: "";
	width: 20px;
	height: 20px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 80px;
	background-position: -20px 0;
	vertical-align: top;
	margin: 17px 8px 0 0;
}

.onekey-login-wx {
	margin-bottom: 24px;
}

.onekey-login-wx:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: 0 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-login-phone {
}

.onekey-login-phone:before {
	display: inline-block;
	content: "";
	width: 21px;
	height: 21px;
	background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/sprite_wap_baike_37443f3.png) no-repeat;
	background-size: 84px;
	background-position: -42px 0;
	vertical-align: top;
	margin: 17px 10px 0 0;
}

.onekey-fixed {
	z-index: 100;
	position: fixed;
	top: 0;
	bottom: 0;
	left: 0;
	right: 0;
	background: #fff;
	width: 100%;
	height: 100%;
}

.onekey-fixed.forbid {
	z-index: 100;
	position: fixed;
	top: auto;
	bottom: 68px;
	left: 9%;
	right: 0;
	background: rgba(0, 0, 0, 0.7);
	width: 82%;
	height: 43px;
	border-radius: 25px;
	color: #ffffff;
}
.onekey-login-title.forbid {
	text-align: center;
	padding-bottom: 3px;
	font-size: 14px;
	font-weight: normal;
	line-height: 30px;
	color: white;
}
</style><style>#login_mask {
  background: #000;
  opacity: 0.5;
  filter: alpha(opacity=50);
  position: fixed;
  /*fixed好像在哪个IE上有BUG，先用用*/
  left: 0;
  top: 0;
  z-index: 999;
  height: 100%;
}

#login_iframe_container {
  position: fixed;
  width: 550px;
  height: 360px;
  z-index: 1020;
  background-color: #ffffff;
}

@media screen and (max-width: 828px) {
  #login_iframe_container {
    top: 50% !important;
    left: 50% !important;
    transform: translate(-50%, -50%);
  }
}

#login_iframe_container.new-login {
  width: 550px;
  height: 360px;
  background-image: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/background_2a4a8a6.png);
}

#login_iframe_container.new-login.no-bg {
  background: #fff;
}

#login_iframe_container.new-login .login-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 30px;
  letter-spacing: 0.19px;
  color: #ffffff;
  margin-top: 62px;
}
#login_iframe_container.new-login .forbid-title {
  width: 100%;
  height: 42px;
  line-height: 42px;
  text-align: center;
  font-size: 24px;
  letter-spacing: 0.19px;
  color: #333333;
  margin-top: 150px;
}

#login_iframe_container.new-login.no-bg .login-title {
  color: #333333;
}

#login_iframe_container.new-login .login-subtitle {
  width: 100%;
  height: 18px;
  line-height: 18px;
  font-size: 13px;
  letter-spacing: 0.08px;
  color: #ffffff;
  text-align: center;
  margin-top: 9px;
  margin-bottom: 43px;
}

#login_iframe_container.new-login.no-bg .login-subtitle {
  color: #999999;
}

#login_iframe_container.new-login .login-subtitle::before {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: -5px;
}

#login_iframe_container.new-login .login-subtitle::after {
  content: '';
  display: inline-block;
  width: 10px;
  height: 1px;
  background-color: #ffffff;
  position: relative;
  top: -4px;
  left: 5px;
}

#login_iframe_container.new-login.no-bg .login-subtitle::before {
  background-color: #999999;
}

#login_iframe_container.new-login.no-bg .login-subtitle::after {
  background-color: #999999;
}

#login_iframe_container.new-login .close-btn {
  position: absolute;
  top: 20px;
  right: 20px;
  width: 12px;
  height: 12px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -59px -10px;
  background-size: 81px 91px;
  cursor: pointer;
}

#login_iframe_container.new-login .login-btn {
  width: 220px;
  height: 47px;
  border-radius: 24px;
  border: solid 1px #dddddd;
  background-color: #ffffff;
  margin: 0 auto;
  margin-top: 28px;
  position: relative;
  display: block;
}

#login_iframe_container.new-login .login-btn .login-icon {
  position: absolute;
}

#login_iframe_container.new-login .login-btn .login-text {
  width: 61px;
  height: 47px;
  line-height: 47px;
  vertical-align: middle;
  font-size: 15px;
  letter-spacing: 0.1px;
  color: #666666;
  position: absolute;
  right: 62px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-icon {
  width: 22px;
  height: 27px;
  top: 10px;
  left: 67px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -54px;
  background-size: 81px 91px;
}

#login_iframe_container.new-login .login-btn.qq-btn .login-text {
  right: 59px;
}

#login_iframe_container.new-login .login-btn.wechat-btn .login-icon {
  width: 29px;
  height: 24px;
  top: 12px;
  left: 62px;
  background: url(//web.archive.org/web/20221028205211/https://hhy.sogoucdn.com/js/common/hhy/login-sprites_e3853e5.png) -10px -10px;
  background-size: 81px 91px;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style><style>/* -- container -- */
.rodal,
.rodal-mask {
    top: 0;
    left: 0;
    width: 100%;
    height: 100%;
    z-index: 100;
}

.rodal {
    position: fixed;
}

/* -- mask -- */
.rodal-mask {
    position: fixed;
    background: rgba(0, 0, 0, .5);
}

/* -- dialog -- */
.rodal-dialog {
    position: absolute;
    z-index: 101;
    background: #fff;
    border-radius: 3px;
    box-shadow: 0 1px 3px rgba(0, 0, 0, .2);
}

.rodal-center {
    top: 50%;
    transform: translateY(-50%);
    left: 0;
    right: 0;
    margin: 0 auto;
}

.rodal-bottom {
    left: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

.rodal-top {
    left: 0;
    right: 0;
    top: 0;
    margin: auto;
}

.rodal-left {
    top: 0;
    left: 0;
    bottom: 0;
    margin: auto;
}

.rodal-right {
    top: 0;
    right: 0;
    bottom: 0;
    margin: auto;
}

/* -- close button -- */
.rodal-close {
    position: absolute;
    cursor: pointer;
    top: 16px;
    right: 16px;
    width: 16px;
    height: 16px;
}

.rodal-close:before,
.rodal-close:after {
    position: absolute;
    content: '';
    height: 2px;
    width: 100%;
    top: 50%;
    left: 0;
    margin-top: -1px;
    background: #999;
    border-radius: 100%;
    -webkit-transition: background .2s;
    transition: background .2s;
}

.rodal-close:before {
    -webkit-transform: rotate(45deg);
    transform: rotate(45deg);
}

.rodal-close:after {
    -webkit-transform: rotate(-45deg);
    transform: rotate(-45deg);
}

.rodal-close:hover:before,
.rodal-close:hover:after {
    background: #333;
}

/* -- fade -- */
/* @-webkit-keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

@keyframes rodal-fade-enter {
    from {
        opacity: 0;
    }
}

.rodal-fade-enter {
    -webkit-animation: rodal-fade-enter both ease-in;
    animation: rodal-fade-enter both ease-in;
} */

@-webkit-keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

@keyframes rodal-fade-leave {
    to {
        opacity: 0
    }
}

.rodal-fade-leave {
    -webkit-animation: rodal-fade-leave both ease-out;
    animation: rodal-fade-leave both ease-out;
}

/* -- zoom -- */
@-webkit-keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-enter {
    from {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-enter {
    -webkit-animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-zoom-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

@keyframes rodal-zoom-leave {
    to {
        -webkit-transform: scale3d(.3, .3, .3);
        transform: scale3d(.3, .3, .3);
    }
}

.rodal-zoom-leave {
    -webkit-animation: rodal-zoom-leave both;
    animation: rodal-zoom-leave both;
}

/* -- slideDown -- */
@-webkit-keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-enter {
    from {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-enter {
    -webkit-animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideDown-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

@keyframes rodal-slideDown-leave {
    to {
        -webkit-transform: translate3d(0, -100px, 0);
        transform: translate3d(0, -100px, 0);
    }
}

.rodal-slideDown-leave {
    -webkit-animation: rodal-slideDown-leave both;
    animation: rodal-slideDown-leave both;
}

/* -- slideLeft -- */
@-webkit-keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-enter {
    from {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-enter {
    -webkit-animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideLeft-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

@keyframes rodal-slideLeft-leave {
    to {
        -webkit-transform: translate3d(-150px, 0, 0);
        transform: translate3d(-150px, 0, 0);
    }
}

.rodal-slideLeft-leave {
    -webkit-animation: rodal-slideLeft-leave both;
    animation: rodal-slideLeft-leave both;
}

/* -- slideRight -- */
@-webkit-keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-enter {
    from {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-enter {
    -webkit-animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-slideRight-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

@keyframes rodal-slideRight-leave {
    to {
        -webkit-transform: translate3d(150px, 0, 0);
        transform: translate3d(150px, 0, 0);
    }
}

.rodal-slideRight-leave {
    -webkit-animation: rodal-slideRight-leave both;
    animation: rodal-slideRight-leave both;
}

/* -- slideUp -- */
@-webkit-keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-enter {
    from {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-enter {
    -webkit-animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
    animation: rodal-slideUp-enter both cubic-bezier(0.23, 1, 0.32, 1);
}

@-webkit-keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

@keyframes rodal-slideUp-leave {
    to {
        -webkit-transform: translate3d(0, 100px, 0);
        transform: translate3d(0, 100px, 0);
    }
}

.rodal-slideUp-leave {
    -webkit-animation: rodal-slideUp-leave both;
    animation: rodal-slideUp-leave both;
}

/* -- flip -- */
@-webkit-keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

@keyframes rodal-flip-enter {
    from {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 60deg);
    }

    70% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }
}

.rodal-flip-enter {
    -webkit-animation: rodal-flip-enter both ease-in;
    animation: rodal-flip-enter both ease-in;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

@-webkit-keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

@keyframes rodal-flip-leave {
    from {
        -webkit-transform: perspective(400px);
        transform: perspective(400px);
    }

    30% {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
        transform: perspective(400px) rotate3d(1, 0, 0, -15deg);
    }

    to {
        -webkit-transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
        transform: perspective(400px) rotate3d(1, 0, 0, 45deg);
    }
}

.rodal-flip-leave {
    -webkit-animation: rodal-flip-leave both;
    animation: rodal-flip-leave both;
    -webkit-backface-visibility: visible !important;
    backface-visibility: visible !important;
}

/* -- rotate -- */
@-webkit-keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-enter {
    from {
        -webkit-transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, -180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-enter {
    -webkit-animation: rodal-rotate-enter both;
    animation: rodal-rotate-enter both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

@-webkit-keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

@keyframes rodal-rotate-leave {
    to {
        -webkit-transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
        transform: rotate3d(0, 0, 1, 180deg) scale3d(.3, .3, .3);
    }
}

.rodal-rotate-leave {
    -webkit-animation: rodal-rotate-leave both;
    animation: rodal-rotate-leave both;
    -webkit-transform-origin: center;
    transform-origin: center;
}

/* -- door -- */
@-webkit-keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

@keyframes rodal-door-enter {
    from {
        -webkit-transform: scale3d(0, 1, 1);
        transform: scale3d(0, 1, 1);
    }
}

.rodal-door-enter {
    -webkit-animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
    animation: rodal-door-enter both cubic-bezier(0.4, 0, 0, 1.5);
}

@-webkit-keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

@keyframes rodal-door-leave {
    60% {
        -webkit-transform: scale3d(.01, 1, 1);
        transform: scale3d(.01, 1, 1);
    }

    to {
        -webkit-transform: scale3d(0, 1, .1);
        transform: scale3d(0, 1, .1);
    }
}

.rodal-door-leave {
    -webkit-animation: rodal-door-leave both;
    animation: rodal-door-leave both;
}</style></head><body class=""><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
</style>
<script>__wm.rw(0);</script>
<div id="wm-ipp-base" lang="en" style="display: block; direction: ltr;">
</div><div id="wm-ipp-print">The Wayback Machine - https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm</div>
<script type="text/javascript">//<![CDATA[
__wm.bt(675,27,25,2,"web","https://baike.sogou.com/kexue/d15537804402491912.htm","20221028215537",1996,"/_static/",["/_static/css/banner-styles.css?v=S1zqJCYt","/_static/css/iconochive.css?v=qtvMKcIJ"], false);
  __wm.rw(1);
//]]></script>
<!-- END WAYBACK TOOLBAR INSERT --><script>window._gtag=window._gtag||{};window._gtag.shouldGrayed = false;if ('9b6d819d1feb48f2a08386f163bed2b2') window._gtag.traceId = '9b6d819d1feb48f2a08386f163bed2b2';if ({"illegality":true}) window.userInfo = {"illegality":true};</script><div class="topnavbox"><ul class="topnav"><li><a href="https://web.archive.org/web/20221028215537/https://www.sogou.com/web?query=">网页</a></li><li><a href="https://web.archive.org/web/20221028215537/https://weixin.sogou.com/weixin?p=75351201">微信</a></li><li><a href="https://web.archive.org/web/20221028215537/https://zhihu.sogou.com/zhihu?p=75351218">知乎</a></li><li><a href="https://web.archive.org/web/20221028215537/https://pic.sogou.com/pics?query=">图片</a></li><li><a href="https://web.archive.org/web/20221028215537/https://v.sogou.com/v?query=">视频</a></li><li><a href="https://web.archive.org/web/20221028215537/https://mingyi.sogou.com/">医疗</a></li><li class="cur"><strong>科学</strong></li><li><a href="https://web.archive.org/web/20221028215537/https://hanyu.sogou.com/">汉语</a></li><li><a href="https://web.archive.org/web/20221028215537/https://wenwen.sogou.com/">问问</a></li><li><a href="https://web.archive.org/web/20221028215537/https://www.sogou.com/docs/more.htm">更多<span class="topraquo">»</span></a></li></ul></div><div id="header"><div class="header-wrap"><a class="header-logo" href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue"></a><div class="header-search"><div class="querybox" id="suggBox"><form><input id="searchInput" class="query" type="text" placeholder="搜科学领域专业百科词条" name="query" autocomplete="off" value=""><a href="javascript:;" class="query-search"></a></form></div></div><div class="header-rgt"><span class="btn-header-rgt btn-edit" id="editLemma">创建</span><div class="header-user no-login"></div></div></div></div><div class="fixed-placeholder" style="visibility:none"></div><div id="container" class=""><div class="content lemma-level1"><div class="detail-title" id="abstract-title"><h1>表皮生长因子受体</h1><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#!" class="detail-edit">编辑</a></div><div class="section_content" data-id="60049615470263813"><div><p>表皮生长因子受体（Epidermal growth factor receptor, EGFR）是一种负责与表皮生长因子（EGF）结合的跨膜受体蛋白，具有酪氨酸激酶活性，与EGF结合后可通过多条信号通路促进细胞分裂与增殖。表皮生长因子受体是由美国生物化学家斯坦利·科恩（Stanley Cohen）在发现表皮生长因子时一并发现的，科恩也因此荣获1986年诺贝尔生理与医学奖。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_1" class="kx_ref">[1]</a></sup>近年来，表皮生长因子受体被发现与许多癌症的发生和进展有着密切联系，针对表皮生长因子受体的抑制剂也成为了抗癌领域的研究热点。</p></div></div><div id="catalog"><h2 class="title2">目录<a href="javascript:" class="detail-edit">编辑</a></h2><div class="catalog_wrap" style=""><ul class="catalog_list col2"><li><span class="order">1</span><a href="javascript:" data-level="1" data-id="16087438631895308">结构和机理</a></li><li><span class="order">2</span><a href="javascript:" data-level="1" data-id="16087438631895309">生理功能和病理作用</a></li><li><span class="order">3</span><a href="javascript:" data-level="1" data-id="16087438631895310">相关药物研究</a></li><li class="secondary_catalog"><span>3.1 </span><a href="javascript:" data-id="16087438631895310">EGFR抑制剂</a></li></ul><ul class="catalog_list col2"><li class="secondary_catalog"><span>3.2 </span><a href="javascript:" data-id="16087438631895310">耐药性问题</a></li><li class="secondary_catalog"><span>3.3 </span><a href="javascript:" data-id="16087438631895310">医学成像中的应用</a></li><li><span class="order">4</span><a href="javascript:" data-level="1" data-id="references">参考文献</a></li></ul></div></div><div id="paragraphs"><div><div id="par_16087438631895308"><h2 class="title">1 结构和机理<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>作为一种单次跨膜蛋白，表皮生长因子受体的结构可以大致分为三个部分。其胞外部分含623个氨基酸，负责与EGF等配体结合，跨膜部分含23个氨基酸，负责耦联胞外部分和胞内部分，胞内部分含542个氨基酸，活化后具有激酶催化活性并可以与其他胞内蛋白接触，触发下游信号通路。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_2" class="kx_ref">[2]</a></sup>由于单次跨膜蛋白的特殊性，EGFR的完整结构目前仍未能被解析。虽然如此，科学家仍通过X射线晶体衍射、NMR等一系列手段分别对其胞外、胞内和跨膜结构域进行了大量的结构分析，并拼凑出一张较为完整的画面。</p><p></p><div class="text_img ed_imgfloat_embedmiddle">
            <a class="ed_image_link" data-src="https://img01.sogoucdn.com/app/a/200698/1453_1295_20191230142605-2084829886.jpg" data-bigsrc="https://img01.sogoucdn.com/app/a/200698/1453_1295_20191230142605-2084829886.jpg" title="点击查看大图" href="javascript:">
                <img width="480" class="ed_imgfloat_embedmiddle" titlename="EGFR活化机理示意图" bigsrc="https://img01.sogoucdn.com/app/a/200698/1453_1295_20191230142605-2084829886.jpg" data-align="embedmiddle" data-src="https://img01.sogoucdn.com/app/a/200698/1453_1295_20191230142605-2084829886.jpg" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/1453_1295_20191230142605-2084829886.jpg" data-observer="true">
            </a>
            <div class="text_img_title" style="text-align: center;">EGFR活化机理示意图</div>
        </div><p></p><p>EGFR在未与配体结合时主要以单体形式存在于细胞表面。当EGFR与EGF结合后，EGFR的胞外部分形成对称的二聚体，并通过跨膜部分诱导EGFR的胞内部分形成非对称的二聚体，其中一个EGFR的胞内部分被活化并产生激酶（可以使氨基酸磷酸化）活性，并导致另一个EGFR的胞内部分磷酸化。被磷酸化的这个EGFR的胞内部分可以接下来被含SH2/PTB结构域的蛋白识别，并激活一系列下游信号通路。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_3" class="kx_ref">[3]</a></sup></p><p>EGFR调控的下游信号通路非常广泛且复杂，其中研究的较多的有RAS-RAF-MEK-ERK通路（又称MAPK通路）、PI3K-AKT-mTOR通路、PLC-γ1-PKC通路等。其中，MAPK通路的调节功能主要是通过活化促分裂基因的转录因子，增加促分裂基因（如CYCLIN-D1）的表达，从而实现促进细胞分裂的作用。而在PI3K-AKT-mTOR通路中，作为细胞能量感受器的mTOR活性增加，导致一系列能量代谢途径的改变（如肿瘤细胞中的Warburg效应），从而满足细胞快速分裂所需的能量供应。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_2" class="kx_ref">[2]</a></sup>正因为EGFR可以从许多角度促进细胞分裂和增殖，EGFR的活性变化在许多癌症的发生或进展中起到了关键作用，使得EGFR成为了抗肿瘤药物研发的热门靶点。</p><p></p><div class="text_img ed_imgfloat_embedmiddle">
            <a class="ed_image_link" data-src="https://img04.sogoucdn.com/app/a/200698/672_498_20191230142621-1722338786.png" data-bigsrc="https://img04.sogoucdn.com/app/a/200698/672_498_20191230142621-1722338786.png" title="点击查看大图" href="javascript:">
                <img width="480" class="ed_imgfloat_embedmiddle" titlename="EGFR下游的部分信号通路，图中主要显示MAPK和PI3K-AKT-mTOR通路。" bigsrc="https://img04.sogoucdn.com/app/a/200698/672_498_20191230142621-1722338786.png" data-align="embedmiddle" data-src="https://img04.sogoucdn.com/app/a/200698/672_498_20191230142621-1722338786.png" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/672_498_20191230142621-1722338786.png" data-observer="true">
            </a>
            <div class="text_img_title" style="text-align: center;">EGFR下游的部分信号通路，图中主要显示MAPK和PI3K-AKT-mTOR通路。</div>
        </div><p></p></div></div><div id="par_16087438631895309"><h2 class="title">2 生理功能和病理作用<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p>表皮生长因子受体在正常个体的生长和发育中有着广泛的生理功能，例如乳腺发育<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_4" class="kx_ref">[4]</a></sup>、骨生长<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_5" class="kx_ref">[5]</a></sup>、皮肤损伤修复<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_6" class="kx_ref">[6]</a></sup>、口腔黏膜损伤修复<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_7" class="kx_ref">[7]</a></sup>等。因此，接受EGFR抑制剂治疗的患者较容易出现皮肤不良反应，包括皮疹/痤疮样皮疹、皮肤干燥、瘙痒和指甲/甲周组织的炎症等。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_8" class="kx_ref">[8]</a></sup>另外，口腔黏膜炎症也是EGFR抑制剂的常见副作用之一。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_8" class="kx_ref">[8]</a></sup></p><p>在癌症的病理中，表皮生长因子受体扮演了重要的角色。有研究表明，在东亚裔人群中，约35%到50%的肺癌患者携带EGFR突变。EGFR突变在非小细胞肺癌，尤其是肺腺癌中最为多见。另外，EGFR突变也更常见于非吸烟者肺癌和年轻肺癌患者中。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_9" class="kx_ref">[9]</a></sup>在结直肠癌中，有报道称60%到80%存在EGFR上调。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_10" class="kx_ref">[10]</a></sup>在胶质母细胞瘤（一种高度恶性的脑癌）中，约50%存在EGFR过表达，另外许多胶质母细胞瘤中还存在一种特殊的EGFR突变（EGFRvIII），该突变导致EGFR无需配体活化便可自发维持活性。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_11" class="kx_ref">[11]</a></sup>在头颈部鳞癌中，约80%到90%存在EGFR过表达。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_12" class="kx_ref">[12]</a></sup>总的来说，约30%的上皮系统肿瘤都与EGFR的突变、过表达或失调密切相关。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_13" class="kx_ref">[13]</a></sup></p></div></div><div id="par_16087438631895310"><h2 class="title">3 相关药物研究<a href="javascript:" class="detail-edit">编辑</a></h2><div class="section_content"><p></p><h3>3.1 <span>EGFR抑制剂</span></h3><p></p><p>由于表皮生长因子受体在癌症中扮演的重要作用，近些年来，有很多针对EGFR的抑制剂进入临床应用。根据作用机理的不同，这些抑制剂大体可以分为两类。第一类抑制剂主要包括针对EGFR胞外结构域的人源化单克隆抗体，它们的作用是阻止配体（如EGF）同EGFR接触，从而减少EGFR被激活的程度。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_2" class="kx_ref">[2]</a></sup>目前美国药监局（FDA）批准的这类抑制剂有西妥昔单抗（Cetuximab）、帕尼单抗（Panitumumab）、耐昔妥珠单抗（Necitumumab）等。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_3" class="kx_ref">[3]</a></sup>另一类EGFR抑制剂是针对EGFR胞内结构域的酪氨酸激酶抑制剂（TKI），它们通常与EGFR的ATP结合位点结合，从而竞争性阻止ATP在该位点结合，导致EGFR无法催化氨基酸磷酸化（即阻止了激酶活性），从而阻止了下游信号传导。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_2" class="kx_ref">[2]</a></sup>这一类抑制剂大部分是小分子，目前FDA批准的有厄洛替尼（Erotinib）、拉帕替尼（Lapatinib）、吉非替尼（Gefitinib）、奈拉提尼（Neratinib）等。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_3" class="kx_ref">[3]</a></sup></p><p></p><h3>3.2 <span>耐药性问题</span></h3><p></p><p>虽然各种EGFR抑制剂的出现一定程度上改善了很多晚期肿瘤患者的预后，但几乎所有的EGFR抑制剂都会在使用一段时间后出现明显的耐药性，从而导致EGFR抑制剂对晚期肿瘤患者的5年生存率改善并不明显。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_4" class="kx_ref">[4]</a></sup>癌细胞对EGFR抑制剂产生耐药性的途径有很多，主要包括以下几种机制<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_5" class="kx_ref">[5]</a></sup>：</p><p>
 </p><ol>
  <li><p>EGFR的过度表达或配体过度表达。耐药肿瘤细胞可以在细胞表面产生更多的EGFR，或者激活EGFR的配体（如肿瘤生长因子TGF-α）过度表达，使得需要更大剂量的抗体才能阻止EGFR被活化。</p></li>
  <li><p>EGFR的变体EGFRvIII。该变体为一截短的EGFR，使得其无需配体活化便可自带激酶活性。有研究表明该变体的出现与耐药性有关。</p></li>
  <li><p>EGFR下游或旁路的信号通路上调。EGFR的下游通路或其他旁路，如RAS、PTEN等蛋白质发生活性增加的突变，抵消了EGFR被抑制的效果。</p></li>
  <li><p>EGFR的ATP结合位点发生突变，导致原来的小分子抑制剂无法有效阻止其激酶活性。这是导致酪氨酸激酶抑制剂耐药的主要原因。例如，在TKI治疗中，EGFR的T790M突变占病人获得性耐药的50%以上。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_6" class="kx_ref">[6]</a></sup></p></li>
  <li><p>EGFR抑制剂导致mTOR活性改变，促进自噬，提高肿瘤细胞适应性。mTOR作为EGFR下游的重要一员，其本身在维持细胞能量代谢中具有重要作用。mTOR活性变化可促使细胞通过增强自噬等途径逃过被“饿死”的命运。</p></li>
 </ol><p></p><p>针对不同的耐药机理，研究人员采用了一系列不同的策略来降低EGFR的耐药性问题。对于EGFR的ATP结合位点突变导致的耐药，通过对这一位点的结构解析，借助计算机模拟等药物设计工具，研究人员可以不断地设计出可以结合EGFR突变体的新型酪氨酸激酶抑制剂，如奥希替尼（Osimertinib）。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_7" class="kx_ref">[7]</a></sup>对于EGFR下游通路或旁路上调导致的耐药，可以通过联合其他靶向药的方式，同时抑制多个通路，以起到最大化杀死癌细胞的效果。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_8" class="kx_ref">[8]</a></sup>另外，利用药物载体同时递送EGFR抑制剂和其他小分子化疗药物可更精确地实现对癌细胞的定向打击，同时减少副作用。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_9" class="kx_ref">[9]</a></sup></p><p></p><h3>3.3 <span>医学成像中的应用</span></h3><p></p><p>作为一种在许多肿瘤细胞表面大量表达的分子，EGFR也可以被用于识别肿瘤的标记物，从而应用在肿瘤的医学成像中。将造影剂连接在EGFR抑制剂（小分子或抗体）上，当该分子与EGFR结合后，即可以实现对肿瘤的特异性识别和成像。根据成像原理的不同，研究人员开发了许多不同的EGFR选择性造影剂。例如，将厄洛替尼和纳米氧化铁颗粒共价结合，可以制成对肿瘤选择性成像的核磁共振造影剂。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_10" class="kx_ref">[10]</a></sup>而碳-11标记过的厄洛替尼可以用于正电子发射断层扫描，有助于筛选适用于EGFR抑制剂治疗的癌症患者，从而实现肿瘤的个体化治疗。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_11" class="kx_ref">[11]</a></sup>西妥昔单抗则通常用Zr-89标记后，用于正电子发射断层扫描成像，该造影剂已进入临床试验阶段。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_12" class="kx_ref">[12]</a></sup>另外，通过将化疗药物、造影剂和抗EFGR抗体连接在一起，可以同时实现肿瘤的诊断和靶向治疗的一体化。<sup><a href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/d15537804402491912.htm#quote_10" class="kx_ref">[10]</a></sup></p></div></div></div></div><div id="references"><h2 class="title" id="par_references">参考文献</h2><ul class="references"><li id="quote_1"><span class="references-num">[1]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/http://www.nobelprize.org/prizes/medicine/1986/press-release/" class="blue">Physiology or Medicine Nobel Prize 1986..</span>Nobel prize.</p></li><li id="quote_2"><span class="references-num">[2]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447962/" class="blue">Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways..</span>NCBI.</p></li><li id="quote_3"><span class="references-num">[3]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/https://www.annualreviews.org/doi/full/10.1146/annurev.biophys.37.032807.125829?casa_token=DUaAe8R0Y1oAAAAA:nQMLd-VrX_5B4BA5oULqgl04zqRAMADeOGtx6GmWZJCliYHn-9JZXMd2DFfN6GfUEcHA3p8dRmv7j2Q" class="blue">Structure-Based View of Epidermal Growth Factor Receptor Regulation..</span>Annual Review of Biophysics.</p></li><li id="quote_4"><span class="references-num">[4]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908768/" class="blue">Mammary Gland Growth Factors: Roles in Normal Development and in Cancer..</span>NCBI.</p></li><li id="quote_5"><span class="references-num">[5]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/https://www.cell.com/trends/endocrinology-metabolism/comments/S1043-2760(09)00139-8" class="blue">The EGFR network in bone biology and pathology..</span>Cell Press.</p></li><li id="quote_6"><span class="references-num">[6]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pubmed/15482488" class="blue">EGFR enhances early healing after cutaneous incisional wounding..</span>NCBI.</p></li><li id="quote_7"><span class="references-num">[7]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/https://www.wjgnet.com/2218-6263/full/v4/i1/22.htm" class="blue">Unraveling the role of epidermal growth factor receptor in oral lesions: Key to non surgical treatment modes..</span>World Journal of Stomatology.</p></li><li id="quote_8"><span class="references-num">[8]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397940/" class="blue">EGFR-TKI不良反应管理专家共识。.</span>NCBI.</p></li><li id="quote_9"><span class="references-num">[9]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/https://egfrcancer.org/about-egfr/" class="blue">Epidermal Growth Factor Receptor in Lung Cancer..</span>EGFResisters.</p></li><li id="quote_10"><span class="references-num">[10]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600187/" class="blue">Colon cancer and the epidermal growth factor receptor..</span>NCBI.</p></li><li id="quote_11"><span class="references-num">[11]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5860944/" class="blue">Epidermal growth factor receptor (EGFR) and EGFRvIII in glioblastoma (GBM)..</span>NCBI.</p></li><li id="quote_12"><span class="references-num">[12]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0063440" class="blue">Overexpression of EGFR in Head and Neck Squamous Cell Carcinoma Is Associated with Inactivation of SH3GL2 and CDC25A Genes..</span>PLoS One.</p></li><li id="quote_13"><span class="references-num">[13]</span><p><a class="ref-back-btn">^</a><span data-url="https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223233/" class="blue">Activation of Epidermal Growth Factor Receptor Is Required for NTHi-Induced NF-κB-Dependent Inflammation..</span>NCBI.</p></li></ul></div><div class="read-num">阅读 <!-- -->1817</div></div><div class="right-side" id="rightSide"><div class="side" id="lemma-side"><div class="side-title">版本记录</div><ul class="side-lst"><li><p class="side-lst-txt">暂无</p></li></ul><div class="user-card userCard"></div></div><div class="side"><div class="side-event"></div></div></div></div><div class="footer-box"><div id="footer"><div class="footer-logo-wrap"><div class="footer-logo"></div><div class="footer-logo-text">知识·传播·科普</div></div><div class="footer-info">本网站内容采用<a target="_blank" href="https://web.archive.org/web/20221028215537/https://creativecommons.org/licenses/by-sa/3.0/deed.zh?tdsourcetag=s_pctim_aiomsg">CC-BY-SA 3.0</a>授权</div><div class="footer-btn-wrap"><a target="_blank" href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/help/#user_protocol">用户协议</a><a target="_blank" href="https://web.archive.org/web/20221028215537/http://www.sogou.com/docs/terms.htm?v=1">免责声明</a><a target="_blank" href="https://web.archive.org/web/20221028215537/http://corp.sogou.com/private.html">隐私政策</a><a target="_blank" href="https://web.archive.org/web/20221028215537/https://baike.sogou.com/kexue/intro.htm">关于我们</a></div></div></div><script>window.lemmaInfo ={"lemmaId":"15537804402491912","versionId":"60049615436709391","title":"表皮生长因子受体","subtitle":"","abstracts":{"paragraphId":"60049615470263813","title":"摘要","versionId":"60049615436709392","lemmaId":15537804402491912,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1603088359,"comment":null,"dependVersionId":0,"contentType":2,"content":"<p>表皮生长因子受体（Epidermal growth factor receptor, EGFR）是一种负责与表皮生长因子（EGF）结合的跨膜受体蛋白，具有酪氨酸激酶活性，与EGF结合后可通过多条信号通路促进细胞分裂与增殖。表皮生长因子受体是由美国生物化学家斯坦利·科恩（Stanley Cohen）在发现表皮生长因子时一并发现的，科恩也因此荣获1986年诺贝尔生理与医学奖。<sup><a href=\"#quote_1\" class=\"kx_ref\">[1]</a></sup>近年来，表皮生长因子受体被发现与许多癌症的发生和进展有着密切联系，针对表皮生长因子受体的抑制剂也成为了抗癌领域的研究热点。</p>","pics":null,"card":null,"references":[],"versionCount":0},"card":{"paragraphId":"0","title":"","versionId":"0","lemmaId":0,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":0,"comment":null,"dependVersionId":0,"contentType":0,"content":"","pics":null,"card":null,"references":null,"versionCount":0},"categories":[{"id":144,"name":"多肽与蛋白质生物化学","parents":[[{"id":4,"name":"生物学","parents":null},{"id":143,"name":"生物化学","parents":null}]]}],"creator":{"uid":77532282,"name":"胡天楠","pic":"https://web.archive.org/web/20221028215537/https://cache.soso.com/thirdwx_qlogo/mmopen/vi_32/Q0j4TwGTfTLlveSnKicrOD8ABGuGOT9lFkMd2wGmfl9v8GXuuCVCL5icB4IXMskU1xtQ1YDP2Yv5orkDQCZicYTIA/132","introduction":"","educations":[{"schoolName":"加州大学戴维斯分校","major":"","degree":"博士","universityId":114,"universityLogo":"","majorLevel1":null,"majorLevel2":null,"majorLevel3":null,"majorLevel1Id":0,"majorLevel2Id":0,"majorLevel3Id":0,"state":"毕业","lab":"","researchField":""}],"jobs":[{"company":"加州大学旧金山分校","title":"Assistant Specialist"}],"works":null,"educationBrief":"加州大学戴维斯分校","jobBrief":"Assistant Specialist","role":0,"roleName":null,"title":"加州大学戴维斯分校 · 博士","professionalTitle":"加州大学旧金山分校助理研究员","phoneNo":null,"editable":true,"partnerId":11,"partnerIdCreateTime":1594286496,"partnerIdPoped":true},"createTime":1576557253,"editor":{"uid":77532282,"name":"胡天楠","pic":"https://web.archive.org/web/20221028215537/https://cache.soso.com/thirdwx_qlogo/mmopen/vi_32/Q0j4TwGTfTLlveSnKicrOD8ABGuGOT9lFkMd2wGmfl9v8GXuuCVCL5icB4IXMskU1xtQ1YDP2Yv5orkDQCZicYTIA/132","introduction":"","educations":[{"schoolName":"加州大学戴维斯分校","major":"","degree":"博士","universityId":114,"universityLogo":"","majorLevel1":null,"majorLevel2":null,"majorLevel3":null,"majorLevel1Id":0,"majorLevel2Id":0,"majorLevel3Id":0,"state":"毕业","lab":"","researchField":""}],"jobs":[{"company":"加州大学旧金山分校","title":"Assistant Specialist"}],"works":null,"educationBrief":"加州大学戴维斯分校","jobBrief":"Assistant Specialist","role":0,"roleName":null,"title":"加州大学戴维斯分校 · 博士","professionalTitle":"加州大学旧金山分校助理研究员","phoneNo":null,"editable":true,"partnerId":11,"partnerIdCreateTime":1594286496,"partnerIdPoped":true},"editTime":1579302348,"state":1,"versionCount":5,"upNum":123,"downNum":0,"pics":[{"originalUrl":"https://web.archive.org/web/20221028215537/https://img01.sogoucdn.com/app/a/200698/1453_1295_20191230142605-2084829886.jpg?w=1453&h=1295&titlename=EGFR%E6%B4%BB%E5%8C%96%E6%9C%BA%E7%90%86%E7%A4%BA%E6%84%8F%E5%9B%BE","url":"https://web.archive.org/web/20221028215537/https://img01.sogoucdn.com/app/a/200698/1453_1295_20191230142605-2084829886.jpg","rw":1453,"rh":1295,"title":"EGFR活化机理示意图","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028215537/https://img04.sogoucdn.com/app/a/200698/672_498_20191230142621-1722338786.png?w=672&h=498&titlename=EGFR%E4%B8%8B%E6%B8%B8%E7%9A%84%E9%83%A8%E5%88%86%E4%BF%A1%E5%8F%B7%E9%80%9A%E8%B7%AF%EF%BC%8C%E5%9B%BE%E4%B8%AD%E4%B8%BB%E8%A6%81%E6%98%BE%E7%A4%BAMAPK%E5%92%8CPI3K-AKT-mTOR%E9%80%9A%E8%B7%AF%E3%80%82","url":"https://web.archive.org/web/20221028215537/https://img04.sogoucdn.com/app/a/200698/672_498_20191230142621-1722338786.png","rw":672,"rh":498,"title":"EGFR下游的部分信号通路，图中主要显示MAPK和PI3K-AKT-mTOR通路。","alt":null,"width":0,"height":0}],"catalogs":[{"level":1,"title":"结构和机理","paragraphId":"16087438631895308","subCatalogs":null},{"level":1,"title":"生理功能和病理作用","paragraphId":"16087438631895309","subCatalogs":null},{"level":1,"title":"相关药物研究","paragraphId":"16087438631895310","subCatalogs":[{"level":2,"title":"EGFR抑制剂","paragraphId":"16087438631895310","subCatalogs":null},{"level":2,"title":"耐药性问题","paragraphId":"16087438631895310","subCatalogs":null},{"level":2,"title":"医学成像中的应用","paragraphId":"16087438631895310","subCatalogs":null}]},{"level":1,"title":"参考文献","paragraphId":"-1","subCatalogs":null}],"paragraphs":[{"paragraphId":"16087438631895308","title":"结构和机理","versionId":"60049615436709393","lemmaId":15537804402491912,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1603088359,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>作为一种单次跨膜蛋白，表皮生长因子受体的结构可以大致分为三个部分。其胞外部分含623个氨基酸，负责与EGF等配体结合，跨膜部分含23个氨基酸，负责耦联胞外部分和胞内部分，胞内部分含542个氨基酸，活化后具有激酶催化活性并可以与其他胞内蛋白接触，触发下游信号通路。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup>由于单次跨膜蛋白的特殊性，EGFR的完整结构目前仍未能被解析。虽然如此，科学家仍通过X射线晶体衍射、NMR等一系列手段分别对其胞外、胞内和跨膜结构域进行了大量的结构分析，并拼凑出一张较为完整的画面。</p><p><img width=\"480\" class=\"ed_imgfloat_embedmiddle\" titlename=\"EGFR活化机理示意图\" bigsrc=\"https://img01.sogoucdn.com/app/a/200698/1453_1295_20191230142605-2084829886.jpg\" data-align=\"embedmiddle\" data-src=\"https://img01.sogoucdn.com/app/a/200698/1453_1295_20191230142605-2084829886.jpg\"></p><p>EGFR在未与配体结合时主要以单体形式存在于细胞表面。当EGFR与EGF结合后，EGFR的胞外部分形成对称的二聚体，并通过跨膜部分诱导EGFR的胞内部分形成非对称的二聚体，其中一个EGFR的胞内部分被活化并产生激酶（可以使氨基酸磷酸化）活性，并导致另一个EGFR的胞内部分磷酸化。被磷酸化的这个EGFR的胞内部分可以接下来被含SH2/PTB结构域的蛋白识别，并激活一系列下游信号通路。<sup><a href=\"#quote_3\" class=\"kx_ref\">[3]</a></sup></p><p>EGFR调控的下游信号通路非常广泛且复杂，其中研究的较多的有RAS-RAF-MEK-ERK通路（又称MAPK通路）、PI3K-AKT-mTOR通路、PLC-γ1-PKC通路等。其中，MAPK通路的调节功能主要是通过活化促分裂基因的转录因子，增加促分裂基因（如CYCLIN-D1）的表达，从而实现促进细胞分裂的作用。而在PI3K-AKT-mTOR通路中，作为细胞能量感受器的mTOR活性增加，导致一系列能量代谢途径的改变（如肿瘤细胞中的Warburg效应），从而满足细胞快速分裂所需的能量供应。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup>正因为EGFR可以从许多角度促进细胞分裂和增殖，EGFR的活性变化在许多癌症的发生或进展中起到了关键作用，使得EGFR成为了抗肿瘤药物研发的热门靶点。</p><p><img width=\"480\" class=\"ed_imgfloat_embedmiddle\" titlename=\"EGFR下游的部分信号通路，图中主要显示MAPK和PI3K-AKT-mTOR通路。\" bigsrc=\"https://img04.sogoucdn.com/app/a/200698/672_498_20191230142621-1722338786.png\" data-align=\"embedmiddle\" data-src=\"https://img04.sogoucdn.com/app/a/200698/672_498_20191230142621-1722338786.png\"></p>","pics":[{"originalUrl":"https://web.archive.org/web/20221028215537/https://img01.sogoucdn.com/app/a/200698/1453_1295_20191230142605-2084829886.jpg?w=1453&h=1295&titlename=EGFR%E6%B4%BB%E5%8C%96%E6%9C%BA%E7%90%86%E7%A4%BA%E6%84%8F%E5%9B%BE","url":"https://web.archive.org/web/20221028215537/https://img01.sogoucdn.com/app/a/200698/1453_1295_20191230142605-2084829886.jpg","rw":1453,"rh":1295,"title":"EGFR活化机理示意图","alt":null,"width":0,"height":0},{"originalUrl":"https://web.archive.org/web/20221028215537/https://img04.sogoucdn.com/app/a/200698/672_498_20191230142621-1722338786.png?w=672&h=498&titlename=EGFR%E4%B8%8B%E6%B8%B8%E7%9A%84%E9%83%A8%E5%88%86%E4%BF%A1%E5%8F%B7%E9%80%9A%E8%B7%AF%EF%BC%8C%E5%9B%BE%E4%B8%AD%E4%B8%BB%E8%A6%81%E6%98%BE%E7%A4%BAMAPK%E5%92%8CPI3K-AKT-mTOR%E9%80%9A%E8%B7%AF%E3%80%82","url":"https://web.archive.org/web/20221028215537/https://img04.sogoucdn.com/app/a/200698/672_498_20191230142621-1722338786.png","rw":672,"rh":498,"title":"EGFR下游的部分信号通路，图中主要显示MAPK和PI3K-AKT-mTOR通路。","alt":null,"width":0,"height":0}],"card":null,"references":[],"versionCount":0},{"paragraphId":"16087438631895309","title":"生理功能和病理作用","versionId":"60049615436709394","lemmaId":15537804402491912,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1603088359,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p>表皮生长因子受体在正常个体的生长和发育中有着广泛的生理功能，例如乳腺发育<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup>、骨生长<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup>、皮肤损伤修复<sup><a href=\"#quote_6\" class=\"kx_ref\">[6]</a></sup>、口腔黏膜损伤修复<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup>等。因此，接受EGFR抑制剂治疗的患者较容易出现皮肤不良反应，包括皮疹/痤疮样皮疹、皮肤干燥、瘙痒和指甲/甲周组织的炎症等。<sup><a href=\"#quote_8\" class=\"kx_ref\">[8]</a></sup>另外，口腔黏膜炎症也是EGFR抑制剂的常见副作用之一。<sup><a href=\"#quote_8\" class=\"kx_ref\">[8]</a></sup></p><p>在癌症的病理中，表皮生长因子受体扮演了重要的角色。有研究表明，在东亚裔人群中，约35%到50%的肺癌患者携带EGFR突变。EGFR突变在非小细胞肺癌，尤其是肺腺癌中最为多见。另外，EGFR突变也更常见于非吸烟者肺癌和年轻肺癌患者中。<sup><a href=\"#quote_9\" class=\"kx_ref\">[9]</a></sup>在结直肠癌中，有报道称60%到80%存在EGFR上调。<sup><a href=\"#quote_10\" class=\"kx_ref\">[10]</a></sup>在胶质母细胞瘤（一种高度恶性的脑癌）中，约50%存在EGFR过表达，另外许多胶质母细胞瘤中还存在一种特殊的EGFR突变（EGFRvIII），该突变导致EGFR无需配体活化便可自发维持活性。<sup><a href=\"#quote_11\" class=\"kx_ref\">[11]</a></sup>在头颈部鳞癌中，约80%到90%存在EGFR过表达。<sup><a href=\"#quote_12\" class=\"kx_ref\">[12]</a></sup>总的来说，约30%的上皮系统肿瘤都与EGFR的突变、过表达或失调密切相关。<sup><a href=\"#quote_13\" class=\"kx_ref\">[13]</a></sup></p>","pics":null,"card":null,"references":[],"versionCount":0},{"paragraphId":"16087438631895310","title":"相关药物研究","versionId":"60049615436709395","lemmaId":15537804402491912,"createType":0,"creator":{"uid":0,"name":null,"pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"createTime":0,"versionEditor":{"uid":78021691,"name":"没时间到白头","pic":null,"introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":null,"jobBrief":null,"role":0,"roleName":null,"title":null,"professionalTitle":null,"phoneNo":null,"editable":false,"partnerId":0,"partnerIdCreateTime":0,"partnerIdPoped":false},"editTime":1603088359,"comment":null,"dependVersionId":0,"contentType":1,"content":"<p><h3>EGFR抑制剂</h3></p><p>由于表皮生长因子受体在癌症中扮演的重要作用，近些年来，有很多针对EGFR的抑制剂进入临床应用。根据作用机理的不同，这些抑制剂大体可以分为两类。第一类抑制剂主要包括针对EGFR胞外结构域的人源化单克隆抗体，它们的作用是阻止配体（如EGF）同EGFR接触，从而减少EGFR被激活的程度。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup>目前美国药监局（FDA）批准的这类抑制剂有西妥昔单抗（Cetuximab）、帕尼单抗（Panitumumab）、耐昔妥珠单抗（Necitumumab）等。<sup><a href=\"#quote_3\" class=\"kx_ref\">[3]</a></sup>另一类EGFR抑制剂是针对EGFR胞内结构域的酪氨酸激酶抑制剂（TKI），它们通常与EGFR的ATP结合位点结合，从而竞争性阻止ATP在该位点结合，导致EGFR无法催化氨基酸磷酸化（即阻止了激酶活性），从而阻止了下游信号传导。<sup><a href=\"#quote_2\" class=\"kx_ref\">[2]</a></sup>这一类抑制剂大部分是小分子，目前FDA批准的有厄洛替尼（Erotinib）、拉帕替尼（Lapatinib）、吉非替尼（Gefitinib）、奈拉提尼（Neratinib）等。<sup><a href=\"#quote_3\" class=\"kx_ref\">[3]</a></sup></p><p><h3>耐药性问题</h3></p><p>虽然各种EGFR抑制剂的出现一定程度上改善了很多晚期肿瘤患者的预后，但几乎所有的EGFR抑制剂都会在使用一段时间后出现明显的耐药性，从而导致EGFR抑制剂对晚期肿瘤患者的5年生存率改善并不明显。<sup><a href=\"#quote_4\" class=\"kx_ref\">[4]</a></sup>癌细胞对EGFR抑制剂产生耐药性的途径有很多，主要包括以下几种机制<sup><a href=\"#quote_5\" class=\"kx_ref\">[5]</a></sup>：</p><p>\n <ol>\n  <li><p>EGFR的过度表达或配体过度表达。耐药肿瘤细胞可以在细胞表面产生更多的EGFR，或者激活EGFR的配体（如肿瘤生长因子TGF-α）过度表达，使得需要更大剂量的抗体才能阻止EGFR被活化。</p></li>\n  <li><p>EGFR的变体EGFRvIII。该变体为一截短的EGFR，使得其无需配体活化便可自带激酶活性。有研究表明该变体的出现与耐药性有关。</p></li>\n  <li><p>EGFR下游或旁路的信号通路上调。EGFR的下游通路或其他旁路，如RAS、PTEN等蛋白质发生活性增加的突变，抵消了EGFR被抑制的效果。</p></li>\n  <li><p>EGFR的ATP结合位点发生突变，导致原来的小分子抑制剂无法有效阻止其激酶活性。这是导致酪氨酸激酶抑制剂耐药的主要原因。例如，在TKI治疗中，EGFR的T790M突变占病人获得性耐药的50%以上。<sup><a href=\"#quote_6\" class=\"kx_ref\">[6]</a></sup></p></li>\n  <li><p>EGFR抑制剂导致mTOR活性改变，促进自噬，提高肿瘤细胞适应性。mTOR作为EGFR下游的重要一员，其本身在维持细胞能量代谢中具有重要作用。mTOR活性变化可促使细胞通过增强自噬等途径逃过被“饿死”的命运。</p></li>\n </ol></p><p>针对不同的耐药机理，研究人员采用了一系列不同的策略来降低EGFR的耐药性问题。对于EGFR的ATP结合位点突变导致的耐药，通过对这一位点的结构解析，借助计算机模拟等药物设计工具，研究人员可以不断地设计出可以结合EGFR突变体的新型酪氨酸激酶抑制剂，如奥希替尼（Osimertinib）。<sup><a href=\"#quote_7\" class=\"kx_ref\">[7]</a></sup>对于EGFR下游通路或旁路上调导致的耐药，可以通过联合其他靶向药的方式，同时抑制多个通路，以起到最大化杀死癌细胞的效果。<sup><a href=\"#quote_8\" class=\"kx_ref\">[8]</a></sup>另外，利用药物载体同时递送EGFR抑制剂和其他小分子化疗药物可更精确地实现对癌细胞的定向打击，同时减少副作用。<sup><a href=\"#quote_9\" class=\"kx_ref\">[9]</a></sup></p><p><h3>医学成像中的应用</h3></p><p>作为一种在许多肿瘤细胞表面大量表达的分子，EGFR也可以被用于识别肿瘤的标记物，从而应用在肿瘤的医学成像中。将造影剂连接在EGFR抑制剂（小分子或抗体）上，当该分子与EGFR结合后，即可以实现对肿瘤的特异性识别和成像。根据成像原理的不同，研究人员开发了许多不同的EGFR选择性造影剂。例如，将厄洛替尼和纳米氧化铁颗粒共价结合，可以制成对肿瘤选择性成像的核磁共振造影剂。<sup><a href=\"#quote_10\" class=\"kx_ref\">[10]</a></sup>而碳-11标记过的厄洛替尼可以用于正电子发射断层扫描，有助于筛选适用于EGFR抑制剂治疗的癌症患者，从而实现肿瘤的个体化治疗。<sup><a href=\"#quote_11\" class=\"kx_ref\">[11]</a></sup>西妥昔单抗则通常用Zr-89标记后，用于正电子发射断层扫描成像，该造影剂已进入临床试验阶段。<sup><a href=\"#quote_12\" class=\"kx_ref\">[12]</a></sup>另外，通过将化疗药物、造影剂和抗EFGR抗体连接在一起，可以同时实现肿瘤的诊断和靶向治疗的一体化。<sup><a href=\"#quote_10\" class=\"kx_ref\">[10]</a></sup></p>","pics":null,"card":null,"references":[],"versionCount":0}],"references":[{"id":1,"type":"web","title":"Physiology or Medicine Nobel Prize 1986.","site":"Nobel prize","url":"https://web.archive.org/web/20221028215537/http://www.nobelprize.org/prizes/medicine/1986/press-release/","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":2,"type":"web","title":"Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways.","site":"NCBI","url":"https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447962/","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":3,"type":"web","title":"Structure-Based View of Epidermal Growth Factor Receptor Regulation.","site":"Annual Review of Biophysics","url":"https://web.archive.org/web/20221028215537/https://www.annualreviews.org/doi/full/10.1146/annurev.biophys.37.032807.125829?casa_token=DUaAe8R0Y1oAAAAA:nQMLd-VrX_5B4BA5oULqgl04zqRAMADeOGtx6GmWZJCliYHn-9JZXMd2DFfN6GfUEcHA3p8dRmv7j2Q","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":4,"type":"web","title":"Mammary Gland Growth Factors: Roles in Normal Development and in Cancer.","site":"NCBI","url":"https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908768/","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":5,"type":"web","title":"The EGFR network in bone biology and pathology.","site":"Cell Press","url":"https://web.archive.org/web/20221028215537/https://www.cell.com/trends/endocrinology-metabolism/comments/S1043-2760(09)00139-8","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":6,"type":"web","title":"EGFR enhances early healing after cutaneous incisional wounding.","site":"NCBI","url":"https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pubmed/15482488","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":7,"type":"web","title":"Unraveling the role of epidermal growth factor receptor in oral lesions: Key to non surgical treatment modes.","site":"World Journal of Stomatology","url":"https://web.archive.org/web/20221028215537/https://www.wjgnet.com/2218-6263/full/v4/i1/22.htm","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":8,"type":"web","title":"EGFR-TKI不良反应管理专家共识。","site":"NCBI","url":"https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397940/","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":9,"type":"web","title":"Epidermal Growth Factor Receptor in Lung Cancer.","site":"EGFResisters","url":"https://web.archive.org/web/20221028215537/https://egfrcancer.org/about-egfr/","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":10,"type":"web","title":"Colon cancer and the epidermal growth factor receptor.","site":"NCBI","url":"https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600187/","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":11,"type":"web","title":"Epidermal growth factor receptor (EGFR) and EGFRvIII in glioblastoma (GBM).","site":"NCBI","url":"https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5860944/","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":12,"type":"web","title":"Overexpression of EGFR in Head and Neck Squamous Cell Carcinoma Is Associated with Inactivation of SH3GL2 and CDC25A Genes.","site":"PLoS One","url":"https://web.archive.org/web/20221028215537/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0063440","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false},{"id":13,"type":"web","title":"Activation of Epidermal Growth Factor Receptor Is Required for NTHi-Induced NF-κB-Dependent Inflammation.","site":"NCBI","url":"https://web.archive.org/web/20221028215537/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223233/","journalName":null,"author":"","press":"","publishYear":"","publishTime":null,"publishPlace":"","page":"","volume":"","quoteTime":null,"quoted":false}],"recommendReferences":null,"auditState":2,"lemmaLevel":1,"origin":0,"originEnTitle":null,"originZhTitle":null,"pv":1817,"auditType":0,"synonyms":null,"showEditTime":"2020.01.18 07:05","auditors":[{"uid":75234227,"name":"7","pic":"https://web.archive.org/web/20221028215537/https://cache.soso.com/qlogo/g?b=oidb&k=plvPjjqaNicMYKMwhI6yKUA&s=100&t=1555919297","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":177,"partnerIdCreateTime":1595844898,"partnerIdPoped":true}],"hasZhishiNav":false,"auditInfos":{"0":[{"versionId":"0","auditTime":1579396916,"auditorId":75234227,"auditUser":{"uid":75234227,"name":"7","pic":"https://web.archive.org/web/20221028215537/https://cache.soso.com/qlogo/g?b=oidb&k=plvPjjqaNicMYKMwhI6yKUA&s=100&t=1555919297","introduction":null,"educations":null,"jobs":null,"works":null,"educationBrief":"","jobBrief":"","role":0,"roleName":null,"title":"","professionalTitle":null,"phoneNo":null,"editable":true,"partnerId":177,"partnerIdCreateTime":1595844898,"partnerIdPoped":true},"auditReason":"通过作者修改","auditSuggest":null,"auditResult":2,"auditAnnotations":null}]},"isHistory":false};</script><script crossorigin="anonymous" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/aegis.min.js.download"></script><script crossorigin="anonymous" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/main_2020092401.js.download"></script><script crossorigin="anonymous" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/jquery-1.11.1.min.js.download"></script><script crossorigin="anonymous" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/main_2022062701.js.download"></script><script crossorigin="anonymous" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/main_66bbe21.js.download"></script><script crossorigin="anonymous" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/react.production.min.js.download"></script><script crossorigin="anonymous" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/react-dom.production.min.js.download"></script><script crossorigin="anonymous" src="./d15537804402491912.表皮生长因子受体 - 搜狗科学百科_files/main_edf0f08.js.download"></script><div id="popControl"><div class="pop-control-mask" style="display: none;"><div class="pop-container"><i class="close-icon"></i><div class="stop-title">搜狗科学百科停止服务运营公告</div><div class="stop-user">亲爱的用户：</div><div class="stop-content">因业务方向调整，搜狗科学百科将于2022年11月11日正式停止服务与运营。届时产品内所有数据将依据相关法律进行删除并关闭服务器，您将无法登录及使用搜狗科学百科，相关内容在平台下线后将无法找回。</div><div class="stop-content">搜狗科学百科是由搜狗推出的科学领域专业百科产品，与搜狗百科为两个独立产品，本次停止服务与运营仅对搜狗科学百科，并不影响搜狗百科产品正常使用，敬请知悉。</div><div class="stop-content">由此给您带来的不便我们深表歉意，敬请谅解。再次感谢您一直以来的陪伴与支持！</div><div class="stop-team">搜狗科学百科产品&amp;运营团队</div><div class="stop-time">2022年10月11日</div></div></div></div>
</body></html>